Medtronic plc (MDT) is likely to grow in the coming quarters, backed by remarkable progress within the Cardiovascular portfolio. The Cranial and Spinal technologies business within the company’s Neuroscience portfolio has been registering strong growth in recent quarters. Favorable solvency is highly encouraging. Meanwhile, macroeconomic challenges may have an adverse impact on the company’s operations. Intense competition from peers is also concerning. In the past year, this Zacks Rank #3 (Hold) stock has ...